Today, we celebrate a significant milestone with the official launch of Cellafa Bioscience, a groundbreaking joint venture between Astellas and Yaskawa Electric Corporation dedicated to advancing cell therapy and transforming innovations to tangible solutions for patients!      Led by CEO Hideto Yamaguchi, Cellafa harnesses the power of AI and robotics to create a seamless system for cell therapy, encompassing everything from process development to GMP manufacturing.      Through this process, Cellafa can achieve high precision and reproducibility in manufacturing using dual-arm robot, ‘Maholo,’ and lower barriers to technology transfer from research to clinical scale.       Watch the video below to learn more about how Cellafa can help startups and academic institutions achieve greater accessibility – including using a new innovative ‘one-click transfer’ system.  Learn more: https://lnkd.in/gtyvkVWu #CellafaBioscience #CellTherapy #innovation  

I'm proud to share the news of the Cellafa Bioscience launch and want to acknowledge the hard work between Yaskawa Electric Corporation and Astellas Pharma to make this new venture a reality. The cell therapy manufacturing process can be challenging, especially for start-ups and academic centers. Cellafa is hoping to accelerate this process by sharing industry-leading cell therapy expertise and cutting-edge robotic technology. I look forward to seeing the innovative work Cellafa does to contribute to patients through the advancement of cell therapy. #ChangingTomorrow #AstellasPioneeringScience

At ISPE Annual meeting and Expo, Astellas team shared the regulatory lessons learned of Maholo project. The audience expressed great interest in Maholo’s capabilities - so here we are. Cellafa Bioscience is a joint venture for Maholo and can help start ups and academic Institutes achieve greater accessibility for cell therapy manufacturing with one-click tech transfer: from process development to GMP manufacturing. Check out the post below for more! #Astellaspharma #Maholo #ISPE #ATMP #celltherapy #oneclicktechtransfer

🌟 AIM Member Highlight: Dash Bio, ⚡ Boston-based Dash Bio is redefining biotech with AI, robotics, and software, delivering fast, transparent bioanalysis that turns weeks into days. From early discovery through late-stage trials, they accelerate drug development and help bring life-saving therapies to patients faster. AIM is proud to support innovative members like Dash Bio who are shaping the future of life sciences! 👉 Learn more: https://okt.to/h4ugqd #AIMMembers #BiotechInnovation #DashBio #AIinHealthcare #LifeSciences #BostonBiotech #DrugDevelopment #Innovation #HealthcareTech #MassBusiness #AIM #AIMHigh #WhatsUrAIM

Autonomous Pharma: The Self-Healing Factory Imagine a pharmaceutical factory that never sleeps, never breaks down, and continuously improves itself. In this episode, we explore how AI, machine learning, and digital twins are transforming pharma manufacturing into truly autonomous, self-healing systems. Discover how predictive maintenance, real-time quality control, and intelligent data orchestration are driving zero-defect production, faster release cycles, and unmatched operational resilience. Learn how forward-thinking pharma leaders are redefining efficiency, compliance, and sustainability — moving beyond automation toward factories that think, learn, and heal themselves. 🎙️ Tune in to uncover how the next era of Pharma 4.0 is already here — intelligent, connected, and self-optimizing.  

AI drug synthesizer Chemify raises $50 million: Scottish firm will use the cash to advance its robotics and AI platform to rapidly make novel molecules https://lnkd.in/dgdPmbQx (below is a photo of Lee Cronin, Chemify's founder and CEO in the firm's labs in Glasgow).

This past week at Future Labs Live USA, I spoke about how integrating AI with robotics can do more than improve efficiency, it can fundamentally reinvent the R&D ethos in our industry. When we started Intrepid Labs just over two years ago, our vision was to re-engineer formulation development through AI-driven decisions, autonomous preparation and characterization, and continuous learning. Our goal has never been to simply go faster, but to build a smarter process that accelerates the delivery of better medicines to patients. In my keynote, I shared our perspective on what “digital-by-design” drug development looks like:   💡 AI expanding the formulation design space, revealing options no human could test manually.   ✍ Designing with scalable manufacturing in mind from day one.   🧬 Anchoring every decision on the patient’s target product profile. It was great to see familiar faces and new partners in the room and to see these ideas spark such thoughtful discussion, especially around our case studies on the development of liquid and solid oral dosage forms, as well as long-acting injectables. We look forward to continuing the conversation and returning next year! #FutureLabsLive #AI #Formulation #Biotech 

Cell X Technologies is excited to attend the ISSCR International Symposium in Boston - continuing the critical conversation on how we accelerate the future of advanced therapies. Today, iPSC and advanced cell therapies stand at an inflection point. The science is clear. The potential is enormous. But scaling from research breakthrough to clinical reality continues to face real barriers: -Manufacturing complexity -High development & labor costs -Long timelines & slow tech transfer -Variability and operator-driven inconsistency -Regulatory documentation burdens -Fragmented tool & data ecosystems At Cell X, we are addressing these bottlenecks with an integrated, small-footprint automation platform that combines high-resolution imaging, precision robotics, and intelligent, purpose-built software. Our system doesn’t just automate tasks inside a closed box — it coordinates seamlessly across incubators, imaging stations, and supporting instruments, orchestrating complex workflows autonomously and around the clock. Cell X Technologies is proud to be part of a community pushing the automation boundaries —working hand-in-hand with therapeutic developers and reagent innovators — solving real manufacturing challenges today.

I recently looked into the world of robotic pills and am filled with hope for the future of medicine. Imagine taking a pill that doesn’t just dissolve, but actively delivers medicine to the right place in your body, even injecting a biologic drug through the intestinal wall. This technology could transform how we treat chronic diseases that currently require injections - from insulin delivery for diabetics to osteoporosis treatments and certain therapies. I believe the potential benefits are huge and here are some: 1. Greater comfort and convenience for patients 2. Smarter, more targeted delivery of complex drugs 3. Better adherence and accessibility, especially for long-term treatments Although, it's in the early stages with ongoing research and clinical trials, the functionality and effectiveness of this innovation will in the future demonstrate how medicine and robotics can be leveraged to benefit humanity. #medtech #robotics #biotech #medicine #inspiration

Tiny robots, also known as microbots, are making groundbreaking strides in the medical field by navigating through the human bloodstream to deliver targeted drug therapies. These advanced devices are engineered to dissolve after completing their mission, ensuring safety and reducing potential side effects. This innovative method could revolutionize treatments for various conditions by enhancing precision and efficacy. Learn more about this cutting-edge technology and its potential impacts on healthcare at [Nature](https://lnkd.in/d8-bWqF5). #MedicalInnovation #Nanotechnology